MedTrace Logo

Effect of Plasma Rich in Growth Factors in Rotator Cuff Tendinopathy

NCT01915979 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2018-12-20

No results posted yet for this study

Summary

The overall objective of the study is to assess the effectiveness of the treatment of degenerative rotator cuff tendinopathy using the application of plasma rich in growth factors (PRGF).

Main objective:

To show more effectiveness after 6 months of treatment with PRGF, with an improvement in the reference test of more than 15% compared to the treatment with corticosteroids.

Secondary objective:

* To assess the efficacy of the treatment after 12 months.
* Quantification of platelet levels in patients treated with plasma rich in growth factors and its correlation with the clinical effect.

Conditions

  • Rotator Cuff Tendinopathy

Interventions

BIOLOGICAL

Plasma rich in growth factors (PRGF)

DRUG

Celestone cronodose (Bethametasone)

Sponsors & Collaborators

  • Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias

    lead OTHER

Principal Investigators

  • Victor Vaquerizo, MD, PhD · Hospital Universitario Principe de Asturias

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-05-31
Completion
2016-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01915979 on ClinicalTrials.gov